Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology
Jan 10, 2025: Menarini Group, its subsidiary Stemline, and Insilico Medicine ink an exclusive license deal. Stemline gets global rights for a pre - clinical oncology small - molecule addressing high unmet needs.
January 10, 2025
by PR Newswire
Insilico Medicine Raises $255 Million in Series C Financing Led by Warburg Pincus
Insilico Medicine, a global leader in end-to-end artificial intelligence for target discovery, small molecule chemistry, and clinical development, announced that it has closed a $255 million Series C financing led by Warburg Pincus.
June 23, 2021
by prnasia
Insilico announces a multi-target AI-powered drug discovery collaboration with Janssen
Insilico Medicine, a leader in deep generative reinforcement learning for target discovery, small molecule generation, and prediction of clinical trial outcomes, announced that it entered into a multi-target drug discovery agreement with Janssen ...
November 10, 2020
by prnasia
Insilico partners with Taisho on end-to-end AI-powered senolytic drug discovery
Insilico Medicine announced today that Taisho Pharmaceutical Co., Ltd. and Insilico have entered into a research collaboration to identify novel therapeutics against aging.
October 16, 2020
by prnasia
CTFH and Insilico Medicine Enter Al Drug Discovery Collaboration Focused On Accelerating First-in-Class Therapeutics, Worth Up to $200 million
Insilico Medicine, a company developing an end-to-end drug discovery pipeline utilizing the latest advances in deep learning ...
October 11, 2019
by En-CPhI.CN
CTFH, Insilico Medicine enter Al drug discovery collaboration
CTFH is an active adopter of state-of-the-art technologies and has achieved significant milestones in first-in-class drug development.
October 10, 2019
by biospectrumasia
Insilico Medicine secures $37M in series B funding
The Series B funding will be used to commercialize the validated generative chemistry and target identification technology.
September 10, 2019
by biospectrumasia
Insilico Medicine uses AI to transform drug discovery
Invention and scientific validation of GENTRL, an AI-powered system capable of creating new molecules in 21 days.
September 3, 2019
by biospectrumasia
Insilico Medicine Starts Asia's First AI R&D Base in Taiwan, China
The companies will form an alliance with the Center for Biotechnology, the Institute for Information Industry, and TUL Corporation to implement the "AI Digital Health Talent Development Project
March 26, 2018
by biospectrumasia
Leading US Artificial Intelligence Company Insilico Medicine Establishes Asia's First AI R&D Base in Taiwan, China
Developing Taiwan, China's AI Talent together with the Development Center for Biotechnology, Institute for Information Industry, and TUL Corporation
March 23, 2018
by prnasia